Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

Phase 2, Single-Arm Trial of Zanzalintinib (XL092) With MO-03 (CBM588 Capsule) in Patients With Metastatic Renal Cell Carcinoma (mRCC) After Progression to Immunotherapy

This phase II trial tests how well zanzalintinib and MO-03 works for the treatment of renal cell cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that is growing, spreading, or getting worse (progression) after receiving immunotherapy. Zanzalintinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. MO-03 is a type of medication called a microbiome-based immunomodulator. It helps control some of the bacteria found in the gut which may make the zanzalintinib more effective. Giving zanzalintinib with MO-03 may be effective for treating metastatic renal cell cancer after progression on immunotherapy.

Study Overview

• Status: Not yet recruiting
• Conditions: Metastatic Clear Cell Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8
• Intervention / Treatment: Procedure: Computed Tomography; Procedure: Biospecimen Collection; Procedure: Bone Scan; Drug: Zanzalintinib; Drug: C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03

Detailed Description

PRIMARY OBJECTIVE:

I. To evaluate the anti-tumor efficacy of zanzalintinib (XL092) in combination with C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03 (MO-03) in patients with metastatic renal cell carcinoma (mRCC) at second line or third line after disease progression to both a checkpoint inhibitor and cabozantinib, as measured by the objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 criteria.

SECONDARY OBJECTIVES:

I. To assess changes in the gut microbiome composition from baseline to week 12, to understand the impact of CBM588 with XL092 on microbiome modulation.

II. To evaluate microbial diversity changes by comparing the Shannon index from baseline to week 12 with MO-03 and XL092, to explore any association between microbial diversity and treatment response.

III. To examine immune modulation, specifically by measuring changes in the proportion of circulating regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) with the combination of XL092 and MO-03.

IV. To assess cytokine and chemokine levels at various points during the study to evaluate the immunologic response associated with XL092 and MO-03.

V. To evaluate the safety and tolerability of the XL092 and MO-03 combination, focusing on treatment-related toxicities such as diarrhea and nausea, and analyzing all adverse events and serious adverse events per Common Terminology Criteria for Adverse Events (CTCAE) v 6.0.

VI. To analyze survival outcomes, specifically progression-free survival (PFS) and overall survival (OS), using Kaplan-Meier estimates to determine time-to-event distributions and provide an early indication of clinical benefit.

EXPLORATORY OBJECTIVES:

I. To assess the changes in metabolic pathways within the gut microbiome over the course of treatment with XL092 and MO-03.

II. To evaluate the changes in fungal microbiome profiles in response to treatment with XL092 and MO-03.

OUTLINE:

Patients receive XL092 orally (PO) once daily (QD) and MO-03 PO twice daily (BID) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Study treatment may continue after progression if the Investigator believes that the subject is still receiving clinical benefit. Patients undergo computed tomography (CT) scan, bone scan, and blood and urine sample collection throughout the study.

After completion of study treatment, patients are followed up at 30 days and every 12 weeks for 2 years.

• Study Type: Interventional
• Enrollment (Estimated): 34
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • Duarte, California, United States, 91010
      • City of Hope Medical Center
      • Contact: Sumanta K. Pal; Phone Number: 626-256-4673; Email: spal@coh.org
      • Principal Investigator: Sumanta K. Pal

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Capable of understanding and complying with the protocol requirements and must have signed the informed consent document

• Agreement to allow the use of archival tissue from diagnostic tumor biopsies

  • If unavailable, exceptions may be granted with study principal investigator (PI) approval
• Age: ≥ 18 years
• Gender: Males and females are eligible
• Any ethnicity or race
• Eastern Cooperative Oncology Group (ECOG) ≤ 2
• Histologically confirmed renal cell carcinoma with a clear-cell histology
• Patients must have received one or two prior lines of systemic therapy for metastatic disease, which must include prior treatment with a checkpoint inhibitor and cabozantinib (not necessarily in the same line). Prior use of hypoxia-inducible factor (HIF) inhibitors or other tyrosine kinase inhibitors (TKIs) other than cabozantinib are not allowed
• Measurable metastatic disease by RECIST v 1.1 criteria
• Recovery to baseline or ≤ grade 1 severity (CTCAE v 6.0) from adverse events (AEs), including immune-related adverse events (irAEs), related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy (e.g., physiological replacement of corticosteroid). Low-grade or controlled toxicities such as alopecia, ≤ grade 2 hypomagnesemia, ≤ grade 2 neuropathy are permitted)

• White blood cell (WBC) > 2,000/mm^3 (to be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)

  • NOTE: Growth factor is not permitted within 14 days of absolute neutrophil count (ANC) assessment unless cytopenia is secondary to disease involvement

• Neutrophils ≥ 1,500/mm^3 (to be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)

  • NOTE: Growth factor is not permitted within 14 days of absolute neutrophil count (ANC) assessment unless cytopenia is secondary to disease involvement

• Platelets ≥ 100,000/mm^3 (to be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)

  • NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement

• Hemoglobin ≥ 9g/dL (to be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)

  • NOTE: Red blood cell transfusions are not permitted within 14 days of hemoglobin assessment unless cytopenia is secondary to disease involvement
• Total bilirubin ≤ 1.5 X upper limit of normal (ULN) (except for subjects with Gilbert Syndrome, who may have total bilirubin up to 3.0 mg/dL) (to be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)
• Aspartate aminotransferase (AST) ≤ 3.0 x ULN (except for subjects with Gilbert Syndrome, who may have total bilirubin up to 3.0 mg/dL) (to be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)
• Alkaline phosphatase (ALP) ≤ 3.0 x ULN. For subjects with documented bone metastasis ALP ≤ 5 x ULN (to be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)
• Creatinine clearance ≥ 40 mL/min the Cockcroft-Gault formula (to be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)
• If not receiving anticoagulants: International normalized ratio (INR) OR prothrombin (PT) ≤ 1.5 x ULN. If on anticoagulant therapy: PT must be within therapeutic range of intended use of anticoagulants (to be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)
• If not receiving anticoagulants: Activated partial thromboplastin time (aPTT) ≤ 1.2 x ULN, INR ≤ 1.5. If on anticoagulant therapy: aPTT must be within therapeutic range of intended use of anticoagulants (to be performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)

• QT interval corrected by Bazett's formula (QTcB) ≤ 480 ms

  • Note: To be performed within 28 days prior to day 1 of protocol therapy
• If seropositive for HIV, hepatitis C virus (HCV) or hepatitis B virus (HBV), nucleic acid quantitation must be performed. Viral load must be undetectable. HIV-infected, chronic carriers of HBV, and chronic carriers of HCV on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

• Meets other institutional and federal requirements for infectious disease titer requirements

  • Note: Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy
• Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
• Sexually active fertile subjects and their partners must agree to use highly effective method of contraception during the course of the study and for the following durations after the last dose of treatment (whichever is later). An additional contraceptive method, such as a barrier method (e.g., condom), is required. In addition, men must agree not to donate sperm and women must agree not to donate eggs (ova, oocyte) for the purpose of reproduction during these same periods, through 186 days after the last dose of zanzalintinib for women of childbearing potential (WOCBP) or through 96 days after the last dose of zanzalintinib for men

• Female subjects of childbearing potential must not be pregnant at screening. Female subjects are considered to be of childbearing potential unless one of the following criteria is met: permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman > 45 years-of-age in the absence of other biological or physiological causes. In addition, females < 55 years-of-age must have a serum follicle stimulating hormone [FSH] level > 40 mIU/mL to confirm menopause).

  • Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff

Exclusion Criteria:

• Prior treatment with zanzalintinib
• Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment
• Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible

• Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment

  • Note: Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of enrollment.
  • Note: Base of skull lesions without definitive evidence of dural or brain parenchymal involvement are allowed
• Known medical condition (e.g., chronic diarrhea or acute diverticulitis) that, in the investigator's opinion, would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results

• Concomitant anticoagulation with oral anticoagulants (e.g., warfarin, direct thrombin inhibitors ) and platelet inhibitors (e.g., clopidogrel).Allowed anticoagulants are the following:

  • Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).

  • Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen.

    • Note: Subjects must have discontinued oral anticoagulants within 3 days or 5 half-lives prior to first dose of study treatment, whichever is longer
• Any complementary medications (e.g., herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks before first dose of study treatment

• The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:

  • Unstable or deteriorating cardiovascular disorders:

    • Congestive heart failure New York Heart Association Class 3 or 4, class 2 or higher, unstable angina pectoris, new-onset angina, serious cardiac arrhythmias (e.g., ventricular flutter, ventricular fibrillation, Torsades de pointes).
    • Uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment.
    • Stroke (including transient ischemic attack [TIA]), myocardial infarction, or other clinically significant arterial thrombotic and/or ischemic event within 6 months before first dose of study treatment.

    • Pulmonary embolism (PE) or deep vein thrombosis (DVT) or prior clinically significant venous events within 3 months before first dose of study treatment.

      • Note: Subjects with a diagnosis of DVT within 6 months are allowed if asymptomatic and stable at screening and are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen.
      • Note: Subjects who don't require prior anticoagulation therapy may be eligible but must be discussed and approved by the Principal Investigator

• Prior history of myocarditis.

  • Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation:

    • Tumors invading the GI-tract from external viscera.
    • Active peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, or acute pancreatitis.
    • Acute obstruction of the bowel, gastric outlet, or pancreatic or biliary duct within 6 months before first dose unless cause of obstruction is definitively managed and subject is asymptomatic.

    • Abdominal fistula, gastrointestinal perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose.

      • Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment
• Known gastric or esophageal varices
• Ascites, pleural effusion, or pericardial fluid requiring drainage in last 4 weeks
• Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose of study treatment
• Symptomatic cavitating pulmonary lesion(s) or endobronchial disease (asymptomatic or radiated lesions allowed)

• Lesions invading major blood vessel including, but not limited to, inferior vena cava, pulmonary artery, or aorta.

  • Note: Subjects with intravascular tumor extension (e.g., tumor thrombus in renal vein or inferior V. cava) may be eligible following Principal Investigator approval

• Other clinically significant disorders that would preclude safe study participation

  • Active infection requiring systemic treatment. Note: Prophylactic antimicrobial treatments (antibiotics, antimycotic, antiviral) are allowed.

  • Known infection with acute or chronic hepatitis B or C, known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness except for subjects meeting all of the following criteria:

    • (1) Chronic carriers of HBV infection (hepatitis B surface antigen [HBsAg]-positive, anti-hepatitis B core antibody [anti-HBc]-positive) who have undetectable HBV deoxyribonucleic acid (DNA) and are on stable suppressive antiviral therapy.
    • (2) Individuals with prior HCV infection who have completed curative antiviral treatment and achieved undetectable HCV viral load.
    • (3) Chronic carriers of HCV infection who are on stable suppressive antiviral therapy and have undetectable HCV viral load.

    • (4) HIV-infected patients on stable anti-retroviral therapy with CD4+ T cell count ≥ 200/µL; and) an undetectable viral load. *** Note: HIV testing will be performed at screening if and as required by local regulation.

      • Note: To be eligible, participants taking CYP inhibitors (e.g., zidovudine, ritonavir, cobicistat, didanosine) or CYP3 inducers (efavirenz) must change to a different regimen not including these drugs 7 days prior to initiation of study treatment. Anti-retroviral therapies (ART) must have been received for at least 4 weeks prior to the first dose.
      • Note: CD4+ T cell counts, and viral load are monitored per standard of care by the local health care provider.

  • Serious non-healing wound/ulcer/bone fracture.

    • Note: non-healing wounds or ulcers are permitted if due to tumor-associated skin lesions.
  • Malabsorption syndrome.
  • Pharmacologically uncompensated, symptomatic hypothyroidism.
  • Moderate to severe hepatic impairment (Child-Pugh B or C).
  • Requirement for hemodialysis or peritoneal dialysis.
  • History of solid organ or allogeneic stem cell transplant

• Major surgery (e.g., GI surgery, removal or biopsy of brain metastasis) within 8 weeks prior to first dose of study treatment. Prior laparoscopic surgeries (i.e. nephrectomy) within 4 weeks prior to first dose of study treatment. Minor surgery (e.g., simple excision, tooth extraction) within 5 days before first dose of study treatment. Complete wound healing from major or minor surgery must have occurred at least prior to first dose of study treatment

  • Note: Fresh tumor biopsies should be performed at least 5 days before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgical procedures, including biopsies, are not eligible

• Corrected QT interval calculated by the Fridericia formula (QTcF) > 480 ms within 14 days per electrocardiogram (ECG) before first dose of study treatment.

  • Note: Triplicate ECG evaluations will be performed and the average of these 3 consecutive results for QTcF will be used to determine eligibility
• History of psychiatric illness likely to interfere with ability to comply with protocol requirements or give informed consent
• Women who are pregnant or breastfeeding
• Inability to swallow tablets or ingest a suspension either orally or by a nasogastric (NG) or gastrostomy (PEG) tube
• Previously identified allergy or hypersensitivity to components of the study treatment formulations
• Another malignancy that requires active therapy and in the opinion of the Investigator would interfere with monitoring of radiologic assessments of response to Investigational Product, within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy. Incidentally diagnosed prostate cancer is allowed if assessed as stage ≤ T2N0M0 and Gleason score ≤ 6
• Other conditions, which in the opinion of the Investigator, would compromise the safety of the patient or the patient's ability to complete the study
• Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Treatment (zanzalintinib and MO-03); Patients receive XL092 PO QD and MO-03 PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Study treatment may continue after progression if the Investigator believes that the subject is still receiving clinical benefit. Patients undergo CT scan, bone scan, and blood and urine sample collection throughout the study.

Procedure: Computed Tomography; Undergo CT scan; Other Names: CT; CAT; CAT Scan; Computed Axial Tomography; Computerized Axial Tomography; Computerized Tomography; CT Scan; tomography; Computerized axial tomography (procedure); Computerized Tomography (CT) scan; Diagnostic CAT Scan; Diagnostic CAT Scan Service Type; Procedure: Biospecimen Collection; Undergo blood and urine sample collection; Other Names: Biological Sample Collection; Biospecimen Collected; Specimen Collection; Procedure: Bone Scan; Undergo bone scan; Other Names: Bone Scintigraphy; Drug: Zanzalintinib; Given PO; Other Names: XL092; Multi-kinase Inhibitor XL092; XL 092; XL-092; Drug: C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03; Given PO; Other Names: CBM588 Capsule Formulation MO-03; CBM588 Capsule MO-03; Clostridium butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03; Clostridium butyricum CBM 588 Probiotic Strain Capule MO-03; Clostridium butyricum MIYAIRI 588 Capsule Formulation MO-03; MO 03; MO-03; MO03

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall response rate	Will be calculated as the number of patients with complete or partial response (per Response Evaluation Criteria in Solid Tumors version 1.1) divided by the total number of treated/evaluable subjects.	Up to 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in gut microbiota composition in stool	Assessed using the proportion of Bifidobacterium spp.	From baseline to week 12
Microbial diversity	Assessed via comparison of the Shannon index.	From baseline to week 12
Proportion of circulating regulatory T cells	Will be assessed graphically across serial timepoints of blood collection to ascertain any trends.	At baseline, week 9, 13, 17 and 25
Proportion of circulating myeloid-derived suppressor cells	Will be assessed graphically across serial timepoints of blood collection to ascertain any trends.	At baseline, week 9, 13, 17 and 25
Cytokine levels	Will be assessed graphically across serial timepoints of blood collection to ascertain any trends.	At baseline, week 9, 13, 17 and 25
Chemokine levels	Will be assessed graphically across serial timepoints of blood collection to ascertain any trends.	At baseline, week 9, 13, 17 and 25
Treatment related toxicities	Assessed using Common Terminology Criteria for Adverse Events (CTCAE) version (v) 6.0.	From baseline, up to 2 years
Incidence of adverse events	Assessed using CTCAE v 6.0.	Up to 2 years
Incidence of serious adverse events	Assessed using CTCAE v 6.0.	Up to 2 years
Progression free survival	Estimated using the Kaplan-Meier method with 80% confidence bands.	From start of treatment to time of progression or death, up to 2 years
Overall survival	Estimated using the Kaplan-Meier method with 80% confidence bands.	From start of treatment to death from any cause, up to 2 years

Collaborators and Investigators

• Sponsor: City of Hope Medical Center
• Collaborators: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Sumanta K Pal, City of Hope Medical Center

Study record dates

Study Major Dates

• Study Start (Estimated): November 28, 2026
• Primary Completion (Estimated): June 24, 2028
• Study Completion (Estimated): June 24, 2028

Study Registration Dates

• First Submitted: May 5, 2026
• First Submitted That Met QC Criteria: May 5, 2026
• First Posted (Actual): May 11, 2026

Study Record Updates

• Last Update Posted (Actual): May 11, 2026
• Last Update Submitted That Met QC Criteria: May 5, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Male Urogenital Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Urologic Neoplasms; Carcinoma; Kidney Neoplasms; Carcinoma, Renal Cell; Clear-cell metastatic renal cell carcinoma; Investigative Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Specimen Handling
• Other Study ID Numbers: 24926 (Other Identifier: City of Hope Comprehensive Cancer Center); P30CA033572 (U.S. NIH Grant/Contract); NCI-2026-02916 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No